(HT) POST -WHI RE-EVALUATION
The expanded acceptance of hormone therapy (HT) following the re-evaluation of findings from the Women's Health Initiative (WHI)
has significantly influenced the global menopause market. The WHI, initially launched in 1991, aimed to evaluate the health benefits
and risks of HT in postmenopausal women. In 2002, its initial results raised concerns about increased risks of breast cancer,
cardiovascular disease, and stroke, leading to a sharp decline in HT usage. However, subsequent analyses and reinterpretations of the data clarified that these risks vary based on age, overall health status,
and the timing of therapy initiation. For instance, a 2017 study published in Journal of the American Medical Association (JAMA)
suggested that when initiated closer to the onset of menopause, the benefits of HT may outweigh the risks, particularly for symptom
relief and osteoporosis prevention. This more nuanced understanding has prompted a shift in clinical practice, with healthcare
providers increasingly adopting an individualized approach to HT. The North American Menopause Society (NAMS) emphasizes
that, for healthy women within 10 years of menopause onset, HT remains a safe and effective option for managing vasomotor
symptoms and preventing bone loss.
Media coverage, including reports from The New York Times in 2022, has further highlighted
that increased awareness and risk reassessment have contributed to a resurgence in HT prescriptions, particularly across North
America and Europe. Moreover, advancements in formulations such as bioidentical hormones and transdermal delivery systems offer safer and more
personalized treatment options, further driving acceptance. Regulatory bodies, including the U.S. Food and Drug Administration
(FDA), have also updated guidelines to reflect current evidence, supporting more informed decision-making. Overall, the re-
evaluation of WHI data has led to a more balanced perspective, fostering greater confidence among both patients and clinicians in
the use of hormone therapy, and thereby supporting the continued growth of the global menopause market. The increasing shift toward non-hormonal therapies and dietary supplements as a primary approach to managing menopause
symptoms is a significant growth driver for the global menopause market. Women seeking alternatives to hormone replacement
therapy (HRT), which has been associated with certain health risks such as an increased likelihood of breast cancer and
cardiovascular conditions, are increasingly turning to natural and dietary options.
According to the National Institute on Aging, many
women prefer non-hormonal remedies due to their perceived safety and alignment with a more holistic approach to health. This
trend is further supported by rising awareness of the potential side effects of hormonal treatments, along with the growing
popularity of wellness and integrative healthcare practices. Dietary supplements such as black cohosh, red clover, soy isoflavones, and vitamin E are increasingly being used to alleviate
menopausal symptoms, including hot flashes, night sweats, and mood swings. For instance, a 2021 study published in the
Menopause indicated that soy isoflavones may significantly reduce the frequency of hot flashes in menopausal women,
encouraging broader adoption. Moreover, the global rise in health-conscious consumers, coupled with an aging population,
continues to fuel demand for natural products. Governments and health organizations are also playing a supportive role; for
example, the U.S. Food and Drug Administration (FDA) recognizes herbal supplements as complementary options when used
responsibly. Additionally, the expansion of e-commerce platforms has significantly improved access to these non-hormonal solutions, enabling
consumers to conveniently explore and purchase a wide range of dietary supplements.
This trend is further reinforced by media
coverage highlighting the benefits of plant-based and natural remedies, which continues to influence consumer preferences. As more women prioritize personalized, safer, and natural approaches to menopause management, the market for non-hormonal
therapies and dietary supplements is expected to maintain strong growth momentum, driven by increasing awareness and evolving
consumer preferences toward holistic health solutions.
GROWTH IN ONLINE CHANNELS & TELEHEALTH
The rapid growth of online channels and telehealth services has significantly transformed the global menopause management
landscape. As women increasingly seek convenient, discreet, and accessible healthcare options, digital platforms have become
essential for providing information, diagnosis, and treatment solutions. Telehealth enables women to consult healthcare
professionals remotely, reducing barriers such as geographical distance, social stigma, and time constraints associated with
menopause-related concerns.
For instance, the COVID-19 pandemic accelerated telehealth adoption worldwide, with the Centers for Disease Control and
Prevention (CDC) reporting a nearly tenfold increase in telehealth visits in the United States during 2020. This shift enabled women
to access hormone replacement therapy (HRT) consultations, mental health support, and lifestyle guidance without the need for in-
person visits. Moreover, online channels facilitate the widespread dissemination of menopause-related information through
websites, social media, and mobile applications. Platforms such as My Menopause and Menopause Matters offer personalized
advice, symptom trackers, and community support, empowering women to manage their symptoms proactively. According to a
survey published in the Journal of Medical Internet Research, more than 60% of women seeking menopause support prefer digital
tools over traditional
